vs
UiPath, Inc.（PATH）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
UiPath, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的2.0倍（$411.1M vs $207.3M），UiPath, Inc.净利率更高（48.4% vs -62.0%，领先110.4%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 15.9%），UiPath, Inc.自由现金流更多（$25.1M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 0.7%）
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PATH vs RARE — 直观对比
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $411.1M | $207.3M |
| 净利润 | $198.8M | $-128.6M |
| 毛利率 | 83.3% | — |
| 营业利润率 | 3.2% | -54.7% |
| 净利率 | 48.4% | -62.0% |
| 营收同比 | 15.9% | 25.9% |
| 净利润同比 | 1966.2% | 3.5% |
| 每股收益（稀释后） | $0.37 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $411.1M | $207.3M | ||
| Q3 25 | $361.7M | $159.9M | ||
| Q2 25 | $356.6M | $166.5M | ||
| Q1 25 | $423.6M | $139.3M | ||
| Q4 24 | $354.7M | $164.6M | ||
| Q3 24 | $316.3M | $139.5M | ||
| Q2 24 | $335.1M | $147.0M | ||
| Q1 24 | $405.3M | $108.8M |
| Q4 25 | $198.8M | $-128.6M | ||
| Q3 25 | $1.6M | $-180.4M | ||
| Q2 25 | $-22.6M | $-115.0M | ||
| Q1 25 | $51.8M | $-151.1M | ||
| Q4 24 | $-10.7M | $-133.2M | ||
| Q3 24 | $-86.1M | $-133.5M | ||
| Q2 24 | $-28.7M | $-131.6M | ||
| Q1 24 | $33.9M | $-170.7M |
| Q4 25 | 83.3% | — | ||
| Q3 25 | 82.2% | — | ||
| Q2 25 | 82.1% | — | ||
| Q1 25 | 84.8% | — | ||
| Q4 24 | 82.0% | — | ||
| Q3 24 | 80.0% | — | ||
| Q2 24 | 83.5% | — | ||
| Q1 24 | 86.8% | — |
| Q4 25 | 3.2% | -54.7% | ||
| Q3 25 | -5.6% | -106.9% | ||
| Q2 25 | -4.6% | -64.8% | ||
| Q1 25 | 7.9% | -102.6% | ||
| Q4 24 | -12.2% | -74.3% | ||
| Q3 24 | -32.7% | -94.6% | ||
| Q2 24 | -14.8% | -79.1% | ||
| Q1 24 | 3.7% | -151.9% |
| Q4 25 | 48.4% | -62.0% | ||
| Q3 25 | 0.4% | -112.8% | ||
| Q2 25 | -6.3% | -69.0% | ||
| Q1 25 | 12.2% | -108.5% | ||
| Q4 24 | -3.0% | -80.9% | ||
| Q3 24 | -27.2% | -95.7% | ||
| Q2 24 | -8.6% | -89.5% | ||
| Q1 24 | 8.4% | -156.8% |
| Q4 25 | $0.37 | $-1.28 | ||
| Q3 25 | $0.00 | $-1.81 | ||
| Q2 25 | $-0.04 | $-1.17 | ||
| Q1 25 | $0.09 | $-1.57 | ||
| Q4 24 | $-0.02 | $-1.34 | ||
| Q3 24 | $-0.15 | $-1.40 | ||
| Q2 24 | $-0.05 | $-1.52 | ||
| Q1 24 | $0.07 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $-80.0M |
| 总资产 | $2.9B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $1.4B | $421.0M | ||
| Q3 25 | $1.4B | $202.5M | ||
| Q2 25 | $1.6B | $176.3M | ||
| Q1 25 | $1.6B | $127.1M | ||
| Q4 24 | $1.6B | $174.0M | ||
| Q3 24 | $1.7B | $150.6M | ||
| Q2 24 | $1.9B | $480.7M | ||
| Q1 24 | $1.9B | $112.3M |
| Q4 25 | $1.9B | $-80.0M | ||
| Q3 25 | $1.7B | $9.2M | ||
| Q2 25 | $1.7B | $151.3M | ||
| Q1 25 | $1.8B | $144.2M | ||
| Q4 24 | $1.7B | $255.0M | ||
| Q3 24 | $1.8B | $346.8M | ||
| Q2 24 | $2.0B | $432.4M | ||
| Q1 24 | $2.0B | $140.3M |
| Q4 25 | $2.9B | $1.5B | ||
| Q3 25 | $2.6B | $1.2B | ||
| Q2 25 | $2.6B | $1.3B | ||
| Q1 25 | $2.9B | $1.3B | ||
| Q4 24 | $2.7B | $1.5B | ||
| Q3 24 | $2.7B | $1.5B | ||
| Q2 24 | $2.8B | $1.6B | ||
| Q1 24 | $3.0B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $25.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | 6.1% | -48.6% |
| 资本支出强度资本支出/营收 | 0.8% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.14× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $28.3M | $-99.8M | ||
| Q3 25 | $41.6M | $-91.4M | ||
| Q2 25 | $119.0M | $-108.3M | ||
| Q1 25 | $146.1M | $-166.5M | ||
| Q4 24 | $28.1M | $-79.3M | ||
| Q3 24 | $46.4M | $-67.0M | ||
| Q2 24 | $100.0M | $-77.0M | ||
| Q1 24 | $145.6M | $-190.7M |
| Q4 25 | $25.1M | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | $106.2M | $-110.7M | ||
| Q1 25 | $138.7M | $-167.8M | ||
| Q4 24 | $23.2M | $-79.5M | ||
| Q3 24 | $45.0M | $-68.6M | ||
| Q2 24 | $98.8M | $-79.0M | ||
| Q1 24 | $141.8M | $-193.9M |
| Q4 25 | 6.1% | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | 29.8% | -66.5% | ||
| Q1 25 | 32.7% | -120.5% | ||
| Q4 24 | 6.5% | -48.3% | ||
| Q3 24 | 14.2% | -49.2% | ||
| Q2 24 | 29.5% | -53.7% | ||
| Q1 24 | 35.0% | -178.2% |
| Q4 25 | 0.8% | 0.5% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 3.6% | 1.5% | ||
| Q1 25 | 1.7% | 1.0% | ||
| Q4 24 | 1.4% | 0.1% | ||
| Q3 24 | 0.4% | 1.2% | ||
| Q2 24 | 0.4% | 1.4% | ||
| Q1 24 | 0.9% | 3.0% |
| Q4 25 | 0.14× | — | ||
| Q3 25 | 26.25× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.82× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 4.29× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
